(VIANEWS) – SPIE (SPIE.PA), EUROFINS SCIENT. (ERF.PA), TUBIZE-FIN (TUB.BR) are the highest payout ratio stocks on this list.
We have gathered information about stocks with the highest payout ratio up until now. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. SPIE (SPIE.PA)
79.35% Payout Ratio
SPIE SA provides multi-technical services in the areas of energy and communications. The company operates through four segments: France; Germany and Central Europe; North-Western Europe; and Oil & Gas and Nuclear. It provides technical engineering solutions for buildings; technical facility management, energy-efficiency, and technical services for the transmission and distribution of energy for industrial clients; and electrical, mechanical, and HVAC engineering services. The company also offers oil and gas services, including exploring and investigating new fields, buildings and operating facilities, and optimizing production; construction, renovation, and maintenance services for bridges, locks, and pumping stations; maintenance and innovative solutions for traffic infrastructure; and fixed and mobile digital telecom networks, as well as technical building management, communications and networks, tech FM services; engineering, construction, maintenance, and optimization services for industrial processes; energy recovery and sustainable management services to technical facilities; and energy transmission networks, medium-voltage facilities, distribution networks, busbar systems, and wind and solar power farms. In addition, it engages in the installation and maintenance of electrical systems, heating and air conditioning, building ventilation, utilities and automation for industries; and management of IT and data processing infrastructures. The company was founded in 1900 and is headquartered in Cergy-Pontoise, France.
Earnings Per Share
As for profitability, SPIE has a trailing twelve months EPS of €0.92.
PE Ratio
SPIE has a trailing twelve months price to earnings ratio of 29.26. Meaning, the purchaser of the share is investing €29.26 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.32%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 20, 2023, the estimated forward annual dividend rate is 0.77 and the estimated forward annual dividend yield is 2.81%.
Volume
Today’s last reported volume for SPIE is 38889 which is 82.08% below its average volume of 217044.
Yearly Top and Bottom Value
SPIE’s stock is valued at €26.92 at 02:10 EST, under its 52-week high of €29.88 and way higher than its 52-week low of €20.62.
More news about SPIE.
2. EUROFINS SCIENT. (ERF.PA)
43.86% Payout Ratio
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €2.28.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 24.69. Meaning, the purchaser of the share is investing €24.69 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.12%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.9%, now sitting on 6.51B for the twelve trailing months.
Moving Average
EUROFINS SCIENT.’s value is below its 50-day moving average of €57.35 and under its 200-day moving average of €61.56.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jul 4, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1.81%.
Yearly Top and Bottom Value
EUROFINS SCIENT.’s stock is valued at €56.30 at 02:10 EST, way below its 52-week high of €72.64 and above its 52-week low of €52.78.
More news about EUROFINS SCIENT..
3. TUBIZE-FIN (TUB.BR)
43.03% Payout Ratio
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Evenity, an injection for osteoporosis; and Bimzelx to treat moderate to severe plaque psoriasis. The company's products in pipeline include Staccato to treat stereotypical prolonged seizures; Bepranemab for the treatment of Alzheimer's disease; UCB0599 for Parkinson's disease; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize SA is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 34.45. Meaning, the purchaser of the share is investing €34.45 for every euro of annual earnings.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €68.90 at 02:10 EST, way under its 52-week high of €79.90 and higher than its 52-week low of €65.40.
Moving Average
TUBIZE-FIN’s worth is below its 50-day moving average of €71.08 and under its 200-day moving average of €73.52.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 3, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 1.21%.
Volume
Today’s last reported volume for TUBIZE-FIN is 2890 which is 38.49% below its average volume of 4699.
More news about TUBIZE-FIN.
4. ELIS (ELIS.PA)
34.45% Payout Ratio
Elis SA provides flat linen, workwear, and hygiene and well-being solutions in France, Central Europe, Scandinavia, Eastern Europe, the United Kingdom, Ireland, Latin America, Southern Europe, and internationally. The company offers table, bed, kitchen, patient, and bath linens; workwear and personal protective equipment; beverage solutions, such as water coolers and accessories, cups and bottles, and coffee machines; floor protection mats and mops; industrial wipers; and pest and rodent control, insect control, or disinfection services. It also provides washroom hygiene services, such as hand washing and drying, toilet hygiene and urinals, lavatories, and air fragrancing; and reusable cleanroom garments, footwear, goggles, and related contamination control solutions, as well as cleaning systems. In addition, the company offers various solutions for collection and disposal of infectious waste, as well as laundry facilities. It primarily serves the catering, accommodation, healthcare and social welfare, industries, trade and retail, and services sectors, as well as public authorities and administration. Elis SA was founded in 1883 and is headquartered in Saint-Cloud, France.
Earnings Per Share
As for profitability, ELIS has a trailing twelve months EPS of €1.19.
PE Ratio
ELIS has a trailing twelve months price to earnings ratio of 14.79. Meaning, the purchaser of the share is investing €14.79 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.02%.
Moving Average
ELIS’s worth is below its 50-day moving average of €17.74 and above its 200-day moving average of €16.83.
Volume
Today’s last reported volume for ELIS is 26312 which is 90.36% below its average volume of 272976.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.8%, now sitting on 4.14B for the twelve trailing months.
Yearly Top and Bottom Value
ELIS’s stock is valued at €17.60 at 02:10 EST, below its 52-week high of €19.13 and way above its 52-week low of €10.23.
More news about ELIS.
5. CRH PLC ord (CRG.IR)
32.99% Payout Ratio
CRH plc, through its subsidiaries, manufactures and distributes building materials in Ireland and internationally. It operates through three segments: Americas Materials, Europe Materials, and Building Products. The company manufactures and supplies cement, lime, aggregates, precast, ready mixed concrete, and asphalt products; concrete masonry and hardscape products comprising pavers, kerbs, retaining walls, and related patio products; It also offers precast concrete and polymer-based products, such as underground vaults, drainage pipes and structures, utility enclosures, and modular precast structures to the water, energy, communication, transportation, and building structures markets; and construction accessories, such as engineered anchoring, fixing, and connection solutions, as well as lifting systems, formwork accessories, and other accessories used in construction applications. In addition, the company offers network access products, which include composite access chambers, covers, passive safety systems, retention sockets, sealants, and meter boxes; and paving and construction services. Further, it provides building and civil engineering contracting, contract surfacing, operates logistics and owned railway infrastructure; sells and distributes cement; and supplies access chambers and ducting products. CRH plc was founded in 1936 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, CRH PLC ord has a trailing twelve months EPS of €3.6.
PE Ratio
CRH PLC ord has a trailing twelve months price to earnings ratio of 13.98. Meaning, the purchaser of the share is investing €13.98 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.67%.
Yearly Top and Bottom Value
CRH PLC ord’s stock is valued at €50.34 at 02:10 EST, under its 52-week high of €55.00 and way above its 52-week low of €31.80.
Moving Average
CRH PLC ord’s value is under its 50-day moving average of €52.29 and above its 200-day moving average of €46.08.
More news about CRH PLC ord.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
Earnings Before Interest, Taxes, Depreciation, and Amortization
1’s EBITDA is 1.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1% and 1%, respectively.
More news about 1.
